Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 290-317

  Mollenhauer, Brit ^a,b   Parnetti, Lucilla ^c   Rektorova, Irena ^d   Kramberger, Milica G ^e,f,g   Pikkarainen, Maria ^h   Schulz Schaeffer, Walter J ^b   Aarsland, Dag ^f,g   Svenningsson, Per ^f   Farotti, Lucia ^c   Verbeek, Marcel M ⁱ   Schlossmacher, Michael G ^j  

^a PARACELSUS ELENA KLINIK   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF PERUGIA   (Italy)

^d MASARYK UNIVERSITY   (Czech Republic)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f KAROLINSKA INSTITUTE   (Sweden)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ RADBOUD UNIVERSITY   (Netherlands)

^j UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

cerebrospinal fluid biomarker; confounding; dementia; factors; neuropathology; Parkinson's disease; tau protein; synuclein; amyloid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; FLUOXETINE; LEVODOPA; TAU PROTEIN;

ALZHEIMER DISEASE; CHOROID PLEXUS; CLINICAL PROTOCOL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ENDOPHENOTYPE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; HOEHN AND YAHR SCALE; HUMAN; IMMUNOHISTOCHEMISTRY; MINI MENTAL STATE EXAMINATION; MISSENSE MUTATION; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REM SLEEP; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL MEMORY;

EID: 85028252032     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13390     Document Type: Review

References (171)

1. Aarsland D. and Kurz M. W. (2010) The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 20, 633–639.
2. Aarsland D., Litvan I., Salmon D., Galasko D., Wentzel-Larsen T. and Larsen J. P. (2003) Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 1215–1220.
3. Aarsland D., Bronnick K., Larsen J. P., Tysnes O. B. and Alves G. (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72, 1121–1126.
4. Aasly J. O., Johansen K. K., Bronstad G. et al. (2014) Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248.
5. Adler C. H., Beach T. G., Hentz J. G. et al. (2014) Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 83, 406–412.
6. Aerts M. B., Esselink R. A., Abdo W. F., Bloem B. R. and Verbeek M. M. (2012) CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33, e431–e433.
7. Albin R. L., Koeppe R. A., Bohnen N. I., Wernette K., Kilbourn M. A. and Frey K. A. (2008) Spared caudal brainstem SERT binding in early Parkinson's disease. J. Cereb. Blood Flow Metab. 28, 441–444.
8. Alves G., Bronnick K., Aarsland D. et al. (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080–1086.
9. Alves G., Pedersen K. F., Bloem B. R. et al. (2013) Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 84, 537–543.
10. Alves G., Lange J., Blennow K., Zetterberg H., Andreasson U., Forland M. G., Tysnes O. B., Larsen J. P. and Pedersen K. F. (2014) CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology 82, 1784–1790.
11. Andersson M., Zetterberg H., Minthon L., Blennow K. and Londos E. (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriatr. Psychiatry 26, 100–105.
12. Armstrong R. A., Cairns N. J. and Lantos P. L. (2000) Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 187–192.
13. Bartels T., Choi J. G. and Selkoe D. J. (2011) alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107–110.
14. Bateman R. J., Wen G., Morris J. C. and Holtzman D. M. (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68, 666–669.
15. Bateman R. J., Xiong C., Benzinger T. L. et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795–804.
16. Bech S., Hjermind L. E., Salvesen L. et al. (2012) Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord. 18, 69–72.
17. Beyer M. K., Alves G., Hwang K. S. et al. (2013) Cerebrospinal fluid Abeta levels correlate with structural brain changes in Parkinson's disease. Mov. Disord. 28, 302–310.
18. Bibl M., Mollenhauer B., Esselmann H. et al. (2006) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177–1187.
19. Bibl M., Mollenhauer B., Lewczuk P. (2007a) Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry 12, 671–680.
20. Bibl M., Mollenhauer B., Lewczuk P. et al. (2007b) Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry 12, 671–680.
21. Bibl M., Esselmann H., Lewczuk P., Trenkwalder C., Otto M., Kornhuber J., Wiltfang J. and Mollenhauer B. (2010) Combined analysis of CSF tau, Abeta42, Abeta1-42% and Abeta1-40% in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Alzheimers Dis. 2010, pii: 761571. doi: 10.4061/2010/761571.
22. Bidinosti M., Shimshek D. R., Mollenhauer B., Marcellin D., Schweizer T., Lotz G. P., Schlossmacher M. G. and Weiss A. (2012) Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem. 287, 33691–33705.
23. Bjerke M., Portelius E., Minthon L. et al. (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimers Dis. 2010, pii: 986310. doi: 10.4061/2010/986310.
24. Blennow K., Hampel H., Weiner M. and Zetterberg H. (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144.
25. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G. and Tabaton M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65–67.
26. Braak H. and Braak E. (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357.
27. Brunnstrom H., Rawshani N., Zetterberg H., Blennow K., Minthon L., Passant U. and Englund E. (2010) Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement. 6, 104–109.
28. Brunnstrom H., Hansson O., Zetterberg H., Londos E. and Englund E. (2013) Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. Int. J. Geriatr. Psychiatry 28, 738–744.
29. Buerger K., Ewers M., Pirttila T. et al. (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035–3041.
30. del Campo M., Mollenhauer B., Bertolotto A. et al. (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med. 6, 419–430.
31. Chen C. P., Chen R. L. and Preston J. E. (2012) The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma. Exp. Gerontol. 47, 323–328.
32. Cicognola C., Chiasserini D. and Parnetti L. (2015) Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for Alzheimer's disease: the issue of diurnal variation. Front. Neurol. 6, 143.
33. Clark C. M., Xie S., Chittams J. et al. (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60, 1696–1702.
34. Compta Y., Marti M. J., Ibarretxe-Bilbao N., Junque C., Valldeoriola F., Munoz E., Ezquerra M., Rios J. and Tolosa E. (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24, 2203–2210.
35. Compta Y., Ibarretxe-Bilbao N., Pereira J. B. et al. (2012) Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat. Disord. 18, 941–947.
36. Compta Y., Pereira J. B., Rios J. et al. (2013) Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat. Disord. 19, 717–724.
37. Compta Y., Valente T., Saura J. et al. (2015) Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson's disease. J. Neurol. 262, 294–306.
38. Danzer K. M., Kranich L. R., Ruf W. P., Cagsal-Getkin O., Winslow A. R., Zhu L., Vanderburg C. R. and McLean P. J. (2012) Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42.
39. De Meyer G., Shapiro F., Vanderstichele H. et al. (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949–956.
40. Edison P., Rowe C. C., Rinne J. O. et al. (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J. Neurol. Neurosurg. Psychiatry 79, 1331–1338.
41. Eisbach S. E. and Outeiro T. F. (2013) Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. J. Mol. Med. 91, 693–703.
42. El-Agnaf O. M., Salem S. A., Paleologou K. E. et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 1945–1947.
43. El-Agnaf O. M., Salem S. A., Paleologou K. E., Curran M. D., Gibson M. J., Court J. A., Schlossmacher M. G. and Allsop D. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419–425.
44. Emmanouilidou E., Melachroinou K., Roumeliotis T., Garbis S. D., Ntzouni M., Margaritis L. H., Stefanis L. and Vekrellis K. (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838–6851.
45. Engelborghs S., De Vreese K., Van de Casteele T., Vanderstichele H., Van Everbroeck B., Cras P., Martin J. J., Vanmechelen E. and De Deyn P. P. (2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol. Aging 29, 1143–1159.
46. Ennis S. R. and Keep R. F. (2006) The effects of cerebral ischemia on the rat choroid plexus. J. Cereb. Blood Flow Metab. 26, 675–683.
47. Falsone S. F., Leitinger G., Karner A., Kungl A. J., Kosol S., Cappai R. and Zangger K. (2011) The neurotransmitter serotonin interrupts alpha-synuclein amyloid maturation. Biochim. Biophys. Acta 1814, 553–561.
48. Farrer M. J. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306–318.
49. Foulds P. G., Yokota O., Thurston A. et al. (2012) Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol. Dis. 45, 188–195.
50. Frasier M., Chowdhury S., Sherer T. et al. (2010) The Parkinson's progression markers initiative: a prospective biomarker study. Mov. Disord. 25, P340.
51. Frigerio R., Fujishiro H., Ahn T. B. et al. (2011) Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol. Aging 32, 857–863.
52. Gai W. P., Power J. H., Blumbergs P. C. and Blessing W. W. (1998) Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352, 547–548.
53. van Geel W. J., Abdo W. F., Melis R., Williams S., Bloem B. R. and Verbeek M. M. (2008) A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 168, 182–185.
54. Gomez-Tortosa E., Gonzalo I., Fanjul S., Sainz M. J., Cantarero S., Cemillan C., Yebenes J. G. and del Ser T. (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch. Neurol. 60, 1218–1222.
55. Gomperts S. N., Locascio J. J., Rentz D., Santarlasci A., Marquie M., Johnson K. A. and Growdon J. H. (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80, 85–91.
56. Haass C., Schlossmacher M. G., Hung A. Y. et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322–325.
57. Hall S., Öhrfelt A., Constantinescu R. et al. (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch. Neurol. 69, 1445–1452.
58. Hall S., Surova Y., Ohrfelt A., Zetterberg H., Lindqvist D. and Hansson O. (2015) CSF biomarkers and clinical progression of Parkinson disease. Neurology 84, 57–63.
59. Halliday G. M. and McCann H. (2010) The progression of pathology in Parkinson's disease. Ann. N. Y. Acad. Sci. 1184, 188–195.
60. Halliday G. M., Holton J. L., Revesz T. and Dickson D. W. (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187–204.
61. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K. and Minthon L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234.
62. Hansson O., Hall S., Ohrfelt A. et al. (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res. Ther. 6, 25.
63. Hardy J. and Revesz T. (2012) The spread of neurodegenerative disease. N. Engl. J. Med. 366, 2126–2128.
64. Hely M. A., Reid W. G., Adena M. A., Halliday G. M. and Morris J. G. (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844.
65. Hong Z., Shi M., Chung K. A. et al. (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713–726.
66. Hughes A. J., Daniel S. E., Kilford L. and Lees A. J. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181–184.
67. Hughes A. J., Daniel S. E., Ben-Shlomo Y. and Lees A. J. (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861–870.
68. Irwin D. J., White M. T., Toledo J. B. et al. (2012) Neuropathologic substrates of Parkinson disease dementia. Ann. Neurol. 72, 587–598.
69. James B. D., Bennett D. A., Boyle P. A., Leurgans S. and Schneider J. A. (2012) Dementia from Alzheimer disease and mixed pathologies in the oldest old. JAMA 307, 1798–1800.
70. Jellinger K. A. (2003) Neuropathological spectrum of synucleinopathies. Mov. Disord. 18(Suppl 6), S2–S12.
71. Jellinger K. A. (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener. Dis. 5, 118–121.
72. Jellinger K. A. (2012) CSF biomarkers in different phenotypes of Parkinson disease. J. Neural. Transm. 119, 455–456.
73. Jellinger K. A. and Attems J. (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 119, 421–433.
74. Jesse S., Brettschneider J., Sussmuth S. D., Landwehrmeyer B. G., von Arnim C. A., Ludolph A. C., Tumani H. and Otto M. (2011) Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J. Neurol. 258, 1034–1041.
75. Jessen N. A., Munk A. S., Lundgaard I. and Nedergaard M. (2015) The glymphatic system: a Beginner's guide. Neurochem. Res. [Epub ahead of print].
76. Kaerst L., Kuhlmann A., Wedekind D., Stoeck K., Lange P. and Zerr I. (2014) Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. J. Alzheimers Dis. 38, 63–73.
77. Kang J. H., Irwin D. J., Chen-Plotkin A. S. et al. (2013) Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277–1287.
78. Kapaki E., Paraskevas G. P., Emmanouilidou E. and Vekrellis K. (2013) The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS ONE 8, e81654.
79. Kasuga K., Tokutake T., Ishikawa A., Uchiyama T., Tokuda T., Onodera O., Nishizawa M. and Ikeuchi T. (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 81, 608–610.
80. Kerenyi L., Ricaurte G. A., Schretlen D. J. et al. (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch. Neurol. 60, 1223–1229.
81. Koopman K., Le Bastard N., Martin J. J., Nagels G., De Deyn P. P. and Engelborghs S. (2009) Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem. Int. 55, 214–218.
82. Kramer M. L. and Schulz-Schaeffer W. J. (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405–1410.
83. Le Bastard N., Martin J. J., Vanmechelen E., Vanderstichele H., De Deyn P. P. and Engelborghs S. (2010) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol. Aging 31, 1867–1876.
84. Le Bastard N., Coart E., Vanderstichele H., Vanmechelen E., Martin J. J. and Engelborghs S. (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. J. Alzheimers Dis. 33, 117–131.
85. Lee H. J., Suk J. E., Bae E. J. and Lee S. J. (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423–428.
86. Leverenz J. B., Watson G. S., Shofer J., Zabetian C. P., Zhang J. and Montine T. J. (2011) Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 17, 61–64.
87. Louveau A., Smirnov I., Keyes T. J. et al. (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337–341.
88. Mattsson N., Blennow K. and Zetterberg H. (2009) CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann. N. Y. Acad. Sci. 1180, 28–35.
89. Mattsson N., Rosen E., Hansson O. et al. (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468–476.
90. Mecocci P., Parnetti L., Reboldi G. P. et al. (1991) Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol. Scand. 84, 210–213.
91. Mehanna R. and Jankovic J. (2013) Movement disorders in cerebrovascular disease. Lancet Neurol. 12, 597–608.
92. Mignini F., Bronzetti E., Felici L., Ricci A., Sabbatini M., Tayebati S. K. and Amenta F. (2000) Dopamine receptor immunohistochemistry in the rat choroid plexus. J. Auton. Pharmacol. 20, 325–332.
93. Milber J. M., Noorigian J. V., Morley J. F., Petrovitch H., White L., Ross G. W. and Duda J. E. (2012) Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 79, 2307–2314.
94. Moghekar A., Goh J., Li M., Albert M. and O'Brien R. J. (2012) Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort. Arch. Neurol. 69, 246–250.
95. Mollenhauer B., Bibl M., Trenkwalder C. et al. (2005a) Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J. Neural. Transm. 112, 933–948.
96. Mollenhauer B., Cepek L., Bibl M. et al. (2005b) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 19, 164–170.
97. Mollenhauer B., Bibl M., Wiltfang J., Steinacker P., Ciesielczyk B., Neubert K., Trenkwalder C. and Otto M. (2006a) Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin. Chem. Lab. Med. 44, 192–195.
98. Mollenhauer B., Trenkwalder C., von Ahsen N. et al. (2006b) Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200–208.
99. Mollenhauer B., Bibl M., Esselmann H., Steinacker P., Trenkwalder C., Wiltfang J. and Otto M. (2007) Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J. Neural. Transm. 114, 919–927.
100. Mollenhauer B., Cullen V., Kahn I. et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213, 315–325.
101. Mollenhauer B., El-Agnaf O. M., Marcus K., Trenkwalder C. and Schlossmacher M. G. (2010) Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med. 4, 683–699.
102. Mollenhauer B., Esselmann H., Trenkwalder C., Schulz-Schaeffer W., Kretzschmar H., Otto M., Wiltfang J. and Bibl M. (2011a) CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease. J. Alzheimers Dis. 24, 383–391.
103. Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Doring F., Trenkwalder C. and Schlossmacher M. G. (2011b) alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230–240.
104. Mollenhauer B., Trautmann E., Otte B. et al. (2012) alpha-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J. Neural. Transm. 119, 739–746.
105. Mollenhauer B., Trautmann E., Sixel-Doring F. et al. (2013a) Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 81, 1226–1234.
106. Mollenhauer B., Trautmann E., Taylor P., Manninger P., Sixel-Doring F., Ebentheuer J., Trenkwalder C. and Schlossmacher M. G. (2013b) Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44–48.
107. Montine T. J., Shi M., Quinn J. F. et al. (2010) CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682–2685.
108. Mukaetova-Ladinska E. B., Milne J., Andras A. et al. (2008) Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. Dement. Geriatr. Cogn. Disord. 26, 32–42.
109. Mulugeta E., Londos E., Ballard C., Alves G., Zetterberg H., Blennow K., Skogseth R., Minthon L. and Aarsland D. (2011) CSF amyloid beta38 as a novel diagnostic marker for dementia with Lewy bodies. J. Neurol. Neurosurg. Psychiatry 82, 160–164.
110. Nelson P. T., Jicha G. A., Kryscio R. J., Abner E. L., Schmitt F. A., Cooper G., Xu L. O., Smith C. D. and Markesbery W. R. (2010) Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J. Neurol. 257, 359–366.
111. Noguchi-Shinohara M., Tokuda T., Yoshita M., Kasai T., Ono K., Nakagawa M., El-Agnaf O. M. and Yamada M. (2009) CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 1251, 1–6.
112. Nutu M., Bourgeois P., Zetterberg H. et al. (2013) Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseases. Neuromolecular Med. 15, 169–179.
113. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K. and Zetterberg H. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332–335.
114. Otto M., Wiltfang J., Cepek L. et al. (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58, 192–197.
115. Oueslati A., Ximerakis M. and Vekrellis K. (2014) Protein transmission, seeding and degradation: key steps for alpha-synuclein prion-like propagation. Exp. Neurobiol. 23, 324–336.
116. Parnetti L., Tiraboschi P., Lanari A. et al. (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64, 850–855.
117. Parnetti L., Chiasserini D., Bellomo G. et al. (2011) Cerebrospinal fluid tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428–1435.
118. Parnetti L., Castrioto A., Chiasserini D., Persichetti E., Tambasco N., El-Agnaf O. and Calabresi P. (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9, 131–140.
119. Parnetti L., Farotti L., Eusebi P. et al. (2014) Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's disease. Front. Aging Neurosci. 6, 53.
120. Politis M. and Loane C. (2011) Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal 11, 1726–1734.
121. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D. J. and Piccini P. (2010) Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 40, 216–221.
122. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
123. Prikrylova Vranova H., Mares J., Nevrly M., Stejskal D., Zapletalova J., Hlustik P. and Kanovsky P. (2010) CSF markers of neurodegeneration in Parkinson's disease. J. Neural. Transm. 117, 1177–1181.
124. Prikrylova Vranova H., Mares J., Hlustik P., Nevrly M., Stejskal D., Zapletalova J., Obereigneru R. and Kanovsky P. (2012) Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J. Neural. Transm. 119, 353–362.
125. Reesink F. E., Lemstra A. W., van Dijk K. D. et al. (2010) CSF alpha-synuclein does not discriminate dementia with lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 22, 87–95.
126. Riverol M. and Lopez O. L. (2011) Biomarkers in Alzheimer's disease. Front. Neurol. 2, 46.
127. Roman G. C., Erkinjuntti T., Wallin A., Pantoni L. and Chui H. C. (2002) Subcortical ischaemic vascular dementia. Lancet Neurol. 1, 426–436.
128. Sabbagh M. N., Adler C. H., Lahti T. J. et al. (2009) Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 23, 295–297.
129. Schlossmacher M. (2007) Alpha-synuclein and synucleinopathies, in The Dementias 2 (John H Growdon and Martin R Rossor, eds), pp. 186–215. Butterworth-Heinemann, Oxford.
130. Schlossmacher M. G. and Mollenhauer B. (2010) Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Biomark. Med. 4, 647–650.
131. Schneider J. A., Arvanitakis Z., Leurgans S. E. and Bennett D. A. (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann. Neurol. 66, 200–208.
132. Schoonenboom N. S., Reesink F. E., Verwey N. A. et al. (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47–54.
133. Schulz-Schaeffer W. J. (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120, 131–143.
134. Schulz-Schaeffer W. J. (2012) Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology 79, 2298–2299.
135. Selnes P., Blennow K., Zetterberg H., Grambaite R., Rosengren L., Johnsen L., Stenset V. and Fladby T. (2010) Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Res. 7, 10.
136. Seubert P., Vigo-Pelfrey C., Esch F. et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325–327.
137. Sheline Y. I., West T., Yarasheski K. et al. (2014) An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Sci. Transl. Med. 6, 236re234.
138. Shi M. and Zhang J. (2011) CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease. Lancet Neurol. 10, 681; author's reply 681-683.
139. Shi M., Bradner J., Hancock A. M. et al. (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69, 570–580.
140. Siderowf A., Xie S. X., Hurtig H. et al. (2010) CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055–1061.
141. Simon-Sanchez J., Schulte C., Bras J. M. et al. (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308–1312.
142. Simpson J. E., Wharton S. B., Cooper J. et al. (2010) Alterations of the blood–brain barrier in cerebral white matter lesions in the ageing brain. Neurosci. Lett. 486, 246–251.
143. Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
144. Sjogren M., Davidsson P., Wallin A., Granerus A. K., Grundstrom E., Askmark H., Vanmechelen E. and Blennow K. (2002) Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13, 112–118.
145. Slaets S., Le Bastard N., Theuns J. et al. (2013) Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J. Alzheimers Dis. 35, 137–146.
146. Slats D., Claassen J. A., Spies P. E. et al. (2012) Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol. Aging 33, e831–e839.
147. de Souza L. C., Chupin M., Lamari F., Jardel C., Leclercq D., Colliot O., Lehericy S., Dubois B. and Sarazin M. (2012) CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol. Aging 33, 1253–1257.
148. Spies P. E., Melis R. J., Sjogren M. J., Rikkert M. G. and Verbeek M. M. (2009) Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J. Alzheimers Dis. 16, 363–369.
149. Spies P. E., Slats D., Rikkert M. G., Tseng J., Claassen J. A. and Verbeek M. M. (2011) CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans. Neurosci. Lett. 504, 336–338.
150. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840.
151. Stav A. L., Aarsland D., Johansen K. K., Hessen E., Auning E. and Fladby T. (2015) Amyloid-beta and alpha-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat. Disord. 21, 758–764.
152. Stewart T., Liu C., Ginghina C., Cain K. C., Auinger P., Cholerton B., Shi M. and Zhang J. and Parkinson Study Group, D. I. (2014) Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184, 966–975.
153. Strozyk D., Blennow K., White L. R. and Launer L. J. (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652–656.
154. Suenaga T., Ohnishi K., Nishimura M., Nakamura S., Akiguchi I. and Kimura J. (1994) Bundles of amyloid precursor protein-immunoreactive axons in human cerebrovascular white matter lesions. Acta Neuropathol. 87, 450–455.
155. Tapiola T., Alafuzoff I., Herukka S. K., Parkkinen L., Hartikainen P., Soininen H. and Pirttila T. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382–389.
156. Tinsley R. B., Kotschet K., Modesto D., Ng H., Wang Y., Nagley P., Shaw G. and Horne M. K. (2010) Sensitive and specific detection of alpha-synuclein in human plasma. J. Neurosci. Res. 88, 2693–2700.
157. Tokuda T., Salem S. A., Allsop D., Mizuno T., Nakagawa M., Qureshi M. M., Locascio J. J., Schlossmacher M. G. and El-Agnaf O. M. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162–166.
158. Tokuda T., Qureshi M. M., Ardah M. T. et al. (2010) Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766–1772.
159. Toledo J. B., Brettschneider J., Grossman M., Arnold S. E., Hu W. T., Xie S. X., Lee V. M., Shaw L. M. and Trojanowski J. Q. (2012) CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 124, 23–35.
160. Toledo J. B., Korff A., Shaw L. M., Trojanowski J. Q. and Zhang J. (2013a) CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol. 126, 683–697.
161. Toledo J. B., Xie S. X., Trojanowski J. Q. and Shaw L. M. (2013b) Longitudinal change in CSF tau and Abeta biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126, 659–670.
162. Tschampa H. J., Schulz-Schaeffer W., Wiltfang J., Poser S., Otto M., Neumann M. and Kretzschmar H. A. (2001) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 56, 576.
163. Ubhi K., Inglis C., Mante M. et al. (2012) Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of alpha-synucleinopathy. Exp. Neurol. 234, 405–416.
164. Vranova H. P., Henykova E., Kaiserova M. et al. (2014) Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J. Neurol. Sci. 343, 120–124.
165. Wada-Isoe K., Kitayama M., Nakaso K. and Nakashima K. (2007) Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J. Neurol. Sci. 260, 33–37.
166. Wang Y., Shi M., Chung K. A. et al. (2012) Phosphorylated alpha-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra120.
167. Wennstrom M., Londos E., Minthon L. and Nielsen H. M. (2012) Altered CSF orexin and alpha-synuclein levels in dementia patients. J. Alzheimers Dis. 29, 125–132.
168. Wennstrom M., Surova Y., Hall S., Nilsson C., Minthon L., Bostrom F., Hansson O. and Nielsen H. M. (2013) Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8, e53250.
169. Xie L., Kang H., Xu Q. et al. (2013) Sleep drives metabolite clearance from the adult brain. Science 342, 373–377.
170. Yam P. S., Takasago T., Dewar D., Graham D. I. and McCulloch J. (1997) Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion. Brain Res. 760, 150–157.
171. Zhang J., Sokal I., Peskind E. R. et al. (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526–529.